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Abstract
Background: The role of peri-operative chemotherapy in patients with resected stage IV colorectal cancer (CRC) 
remains to be defined. This study was aimed at evaluating the effectiveness of peri-operative chemotherapy in patients 
with resected stage IV CRC by performing a meta-analysis of relevant trials.
Methods: We performed a literature search to identify trials comparing patients with stage IV CRC receiving peri-
operative chemotherapy and surgery with patients undergoing surgery alone. The hazard ratio (HR) was estimated to 
assess any survival advantage of peri-operative chemotherapy.
Results: Eight trials conducted on a total of 1174 patients were identified by a literature search. In these trials, HR 
estimates suggested that peri-operative chemotherapy yielded no survival advantage over surgery alone (HR, 0.94; 
95%CI, 0.8-1.10; p = 0.43). In a subset analysis on intra-arterial chemotherapy alone, no survival benefit was evident (HR, 
1.0; 95% CI, 0.84-1.21; p = 0.96; I2 = 30%), whereas in the trials involving systemic chemotherapy, the difference between 
the groups approached statistical significance (HR, 0.74; 95% CI, 0.53-1.04; p = 0.08; I2 = 0%). Both peri-operative 
treatment groups had a significant recurrence-free survival benefit (HR, 0.78; 95% CI, 0.65-0.95; P = 0.01 for hepatic 
arterial infusion; and HR, 0.75; 95% CI, 0.62-0.91; p = 0.003 for systemic therapy). The toxicities of chemotherapy were 
acceptable in most trials.
Conclusions: This is the first meta-analysis demonstrating the importance of peri-operative chemotherapy in the 
treatment of resected stage IV CRC. Although the results must be carefully interpreted because of some limitations, 
critical issues were identified that must be resolved by future studies.
Background
Colorectal cancer (CRC) is a leading cause of cancer-
related mortality worldwide with approximately 500.000
deaths annually [1-3]. Nearly 25% of patients with CRC
present with synchronous liver metastases at the time of
initial diagnosis [4]. Recurrences after resection of the
primary tumor will occur in 60%-70% in the liver [5].
Surgery of colorectal liver metastases remains the best
treatment modality for potential cure with a 5-year over-
all survival (OS) rate between 25% and 40% [6-8], but at
present only 20%-35% of all patients are suitable candi-
dates for surgery [5].
The long-term survival rate, even after surgical resec-
tion, is unacceptably low, thus to improve survival of
patients with resected stage IV CRC, the development of
effective peri-operative therapy is essential.
Prospective randomized trials investigating the role of
p o s t - o p e r a t i v e  a d j u v a n t  c h e m o t h e r a p y  i n  p a t i e n t s  w i t h
resected CRC have been performed since the 1980 s.
Local hepatic arterial infusion (HAI) has been investi-
gated as additive or adjuvant therapy after resection of
l i v e r  m e t a s t a s e s  i n  p a t i e n t s  w i t h  C R C  i n  a n  e f f o r t  t o
reduce hepatic recurrence with conflicting results regard-
ing survival benefit [9-13].
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A pooled analysis of two adjuvant systemic chemother-
apy trials reported in 2008 revealed a hazard ratio (HR)
for OS of 0.76 for patients treated with 5 FU/FA. The
result for recurrence-free survival (RFS) was only of mar-
ginal significance and may have been due, in part, to the
fact that both trials used an outdated chemotherapy regi-
men and had to be closed prematurely because of slow
accrual [14]. Subsequently, one randomized trial investi-
gating the role of peri-opera tive chemotherapy using a
more active chemotherapy regimen and a larger number
of accrued patients has been conducted [15].
This study failed to demonstrate a significant improve-
ment in recurrence-free survival for the peri-operative
chemotherapy group in the intent-to-treat population.
Therefore, we performed a meta-analysis using data
from all these trials to determine the effect of peri-opera-
tive chemotherapy on overall survival and recurrence-
free survival in patients with resected stage IV CRC.
Methods
Research Objective
The primary objective of this study was to assess the sur-
vival advantage achieved by adding peri-operative che-
motherapy to surgery in patients with resectable stage IV
CRC.
Searching for Trials
We performed electronic searches of Medline (PubMed),
the Cochrane Library, and the Latin American and Carib-
bean Literature on Health Sciences (LILACS) between
1980 and 23 January 2009. We did not search Embase
because we did not expect to retrieve any additional
information [16].
We conducted the search using the following search
terms based on medical subject headings (MeSH) and
title words (TI): colorectal neoplasms (MeSH) and che-
motherapy, adjuvant (MeSH) or anti-neoplastic com-
bined chemotherapy protocols (MeSH) and neoplasm
seeding (MeSH) or liver neoplasms/secondary (MeSH) or
liver (TI) or hepatic (TI).
To avoid publication bias, both published and unpub-
lished trials were identified through a computer-based
search of the PubMed database and abstracts from the
annual meetings of the American Society of Clinical
Oncology. The set was limited to randomized clinical tri-
als, clinical trials, and meta-analyses. No language
restrictions were applied, thus reducing the potential for
language bias. The search was also guided by a thorough
examination of reference lists of original articles and
review articles.
Selection of Trials
We included only those trials in which patients were ran-
domly assigned to at least two arms (surgery with peri-
operative chemotherapy or surgery alone) and included
only patients with pathologically-proven CRC who were
to undergo curative resection.
Due to the small number of studies, one abstract was
also included [17].
Trials initially designed to randomly assign patients to
surgery, followed by different chemotherapy regimens in
both arms, were considered ineligible [18,19].
Assessment of study quality
The quality of all included studies was examined using
the following criteria of the Cochrane Collaboration: gen-
eration of a random sequence; allocation concealment;
blinding of patients, therapists, or outcome assessors;
analysis of outcomes by intention-to-treat (ITT) and pre-
specification of a primary endpoint. Each criterion was
scored as follows: adequate, inadequate or unclear. Qual-
ity was assessed in duplicate by two independent review-
ers.
Data Abstraction
To avoid bias in the data abstraction process, two observ-
ers (SS and MW) independently abstracted the data from
the trials and compared the results. The following infor-
mation was culled from each report: year of publication;
number of patients; gender; resection status; chemother-
apy regimen; OS; RFS specific toxicity data; performance
status and if available, treatment compliance.
In general, treatment compliance was defined as the
number of patients who received the intended chemo-
therapy as a percentage of all the assessable patients.
The same two investigators repeated data extraction
after some weeks in order to check for concordance. No
relevant differences were noted.
Our meta-analysis was based solely on published data.
A l t h o u g h  w e  s o u g h t  t o  o b t a i n  a d d i t i o n a l  i n f o r m a t i o n
from the principal investigators of the trials to confirm or
update the published data, source data were unavailable.
Quantitative Data Synthesis
The HRs were calculated to estimate how many times
lower the probability of death from any cause was in
patients receiving peri-operative chemotherapy after sur-
gery compared with patients undergoing surgery alone.
The HR provided in the report was used wherever avail-
able with 95% CIs [11,15,17,20].
In two studies, the crude log HR and its variance were
calculated using the abstracted survival probabilities at
each time-point from the Kaplan-Meier (KM) curves,
using the IPD reconstruction technique [9,12].
We preferred the IPD reconstruction technique over
the Parmar method [21] because it was easier to apply
and similarly precise in small sample sizes, such as in the
present trials [22]. Since the survival curves in these arti-
cles contained information on all events (i.e., downwardWieser et al. BMC Cancer 2010, 10:309
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s t e p s )  a n d  c e n s o r i n g s  ( i . e . ,  s p i k e s ) ,  t h i s  a l l o w e d  u s  t o
extract data with precision. In addition, we recalculated p
values and median survival times in order to determine
whether or not the results correlated well with the origi-
nal results.
In studies in which no survival curves were available,
the relative risk (RR) was calculated from published inci-
dence data. The RR denotes a measure of the risk of a cer-
tain event happening in one group compared to the risk
of the same event occurring in another group, but with-
out detailed consideration of follow-up times and com-
pleteness [10,13]. For statistical analyses, HR and RR were
used synonymously. The natural logarithm of the HR (log
HR) was used as effect size, with statistical weight
inversely proportional to the variance of log HR. Since
the HR was estimated to assess the survival advantage
conferred by peri-operative chemotherapy a HR below
unity was taken to indicate that adjuvant chemotherapy
after surgery was superior to surgery alone.
Meta-analysis was first performed using fixed-effect
modelling, which assumes that the treatment effect is
theoretically the same in all studies. A subgroup meta-
analysis was performed for systemic therapy and locore-
gional therapy. In the case of heterogeneity, however, ran-
dom-effect modelling was selected, which assumes that
each study result is randomly distributed around the true
value. Heterogeneity testing was performed by calculat-
ing the Q and I2 statistic. We considered heterogeneity to
be present if the I2 statistic was > 50%.
Potential sources of between-trial heterogeneity were
explored by sensitivity analyses focusing on pre-specified
explanatory variables, such as the type of therapy (locore-
gional vs. systemic) and trial quality.
In addition, we examined how strong the overall results
were influenced by each single trial. This was done by
consecutively omitting every study from the meta-analy-
sis (leave-one-out procedure, Table 1).
To minimise the effects of publication bias, we per-
formed a thorough search for unpublished studies, and
used Begg's funnel plot as an analytical tool to quantify
the potential presence of publication bias.
When we plotted the overall estimates against the vari-
ance (sample size), a skewed asymmetric funnel was
observed in the presence of the Wagman trial (Figure 1),
which as a rather small study with small sample size (and
large variance), would be more prone to publication bias,
while a rather symmetric funnel was formed in the
absence of the Wagman trial (Figure 2)
All analyses were performed using Review Manager
(RevMan, version 5.0; Cochrane Collaboration, Oxford,
England).
We defined a statistical result with a p value < .05 as sig-
nificant.
Results
Patient characteristics
The available demographic characteristics of the 1174
patients entered into the trials are listed in Table 2.
There were 706 males and 438 females. The gender of
30 patients was not further specified [9,15,17,20].
Randomized patients had a median/mean age of < 65
years. The number of metastases varied between one and
six. In one study, only solitary metastases were included
[13].
Trial flow
Our main database search produced 271 potentially rele-
vant references, of which 50 full articles were selected.
Additionally, screening of reference lists led to two trials
published in abstract form [17,23]. All the other searches
yielded no additional, potentially relevant articles. The
trial by Wagman was a six-armed trial. Arms A1 and A2
compared chemotherapy after surgery with surgery alone
and comprised a total of 11 patients. These two arms
were treated as an individual trial and included in our
analysis [13].
Most of the potentially relevant articles had to be
excluded because of having a non-randomised design
[24] or comparing two different chemotherapeutic regi-
mens [18,19]. We excluded the trial by Kemeny et al. [25]
because survival data were not available. One of the
remaining nine trials was only published in abstract form
and did not contain sufficient information [23].
Thus, data from eight trials were included in this meta-
analysis.
Study characteristics
The baseline characteristics of the eight trials are listed in
Table 3.
Table 1: Leave-one-out procedure
All studies 
included
Without 
Nordlinger
Without 
Lorenz
Witout 
Portier
Without 
Langer
Without 
Kemeny
Without 
Rudroff
Without 
Lygidakis
Without 
Wagman
OS (HR) 0.94 NA 0.88 0.98 0.95 0.89 0.93 1.02 0.94
RFS (HR) 0.77 0.75 0.71 0.78 0.76 0.78 0.76 0.80 0.77
Abbreviations: HR: Hazard ratio
OS: overall survival; RFS: recurrence-free survivalWieser et al. BMC Cancer 2010, 10:309
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Twenty - two patients from the Langer trial [17] and
two patients from the Portier trial [20] were excluded
from analysis because there were no complete post base-
line data available. Twelve patients from the Rudroff trial
[12] were not randomized and therefore excluded. Due to
multi - arm design eighty patients from the Wagman trial
were also excluded from our analysis [13]. In total, 1058
patients were analyzed, 525 patients who were random-
ized to surgery with peri-operative chemotherapy and
533 patients who were randomized to surgery alone. Five
studies included the majority of patients (977 of 1058
[92.3%]) [9,11,15,17,20].
In the peri-operative chemotherapy arm, 5 FU/FA was
applied systemically in two trials including 278 patients
[17,20] and via continous hepatic artery infusion (cHAI)
in one trial [11].
In other trials, 5FU/FA formed the basis for other che-
motherapy regimens with different drugs added [9,10,12].
FOLFOX 4 was used in one large trial, including 364
patients [15]. One trial used cHAI of FUDR only [13].
Peri-operative chemotherapy was applied mainly as adju-
vant treatment, either systemic or regional, or both. One
trial was designed to administer pre- and post-operative
chemotherapy [15].
Although in all studies the main eligibility criterion was
resectable liver metastasis of colorectal origin, the defini-
tion of resectability varied among studies. Surgical proce-
dures consisted of anatomic and non-anatomic resections
in all studies. Since patients were randomised before sur-
gery in most trials, metastasis were defined as potentially
R0. Post-operative resection status was reported in seven
trials, comprising a total of 848 patients. In the Kemeny
trial [9], R0 resection status was not explicitly stated.
Patients in the trials by Portier et al. and Langer et al.
[20,17] were evaluated monthly throughout the adjuvant
treatment period.
Thereafter patient follow-up was performed every
t h r e e  m o n t h s  f o r  t w o  y e a r s ,  t h e n  o n c e  p e r  y e a r  u n t i l
death or the end of the study in the Portier trial [20]. In
the Langer trial patients were evaluated three and six
months after the end of treatment and then every six
months until five years from randomization [17]. In the
trial by Kemeny et al. [9] patients were observed during
and after therapy every three months for the first three
years. In the trial by Rudroff et al. [12] patients were
examined at three months intervals during the first and
second year after surgery, every six months during the
subsequent three years and on a yearly basis thereafter.
In the trial by Lorenz et al. [11] follow-up examinations
were performed every three months for the first two
years after surgery and every six months thereafter. In the
Nordlinger trial [15] follow-up examinations were per-
formed after three cycles of chemotherapy, every three
Figure 1 Funnel-plot. Funnel-plot with the Wagman trial included.Wieser et al. BMC Cancer 2010, 10:309
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months for the first two years after the end of treatment
and every six months thereafter.
In the trial by Lygidakis et al. [10] patient follow-up was
performed every three months for the first year, at four
m o n t h s  i n t e r v a l s  d u r i n g  t h e  s e c o n d  y e a r  a n d  a t  s i x
months intervals during the following years.
Wagman [13] did not provide any information about
follow-up intervals.
We assessed the quality of all the trials using the criteria
of the Cochrane Collaboration. There was a statement on
both randomization and withdrawal in most of the trials.
However, none of the trials were described as double-
blind.
Trials treating at least one-half of patients with the
assigned therapy, which reported an intent-to-treat anal-
ysis and accrued a large number of patients, were consid-
ered high quality [11,15,20].
Figure 2 Funnel - plot. Funnel-plot without the Wagman trial.
Table 2: Patient characteristics
Nordlinger Lorenz Portier Langer Kemeny Rudroff Lygidakis Wagman
Number of pts 
recruited
364 226 173 129 109 42 40 91
Age (years) Median
63
median
61
< 65: 102
≥ 65: 69
< 70: 86
≥ 70: 21
median:
60
median
58
mean:
61,5
mean:
57,8
Male/female 241/
119 (+4)
126/100 99/72
(+2)
70/37
(+22)
67/40
(+2)
18/24 33/7 52/39
Number of 
metastases
1-4 1-6 1-4
(> 4 in 8 pts)
1-4 1-3 1-4
(> 4 in 3 pts)
n.r. 1
PS WHO
≤ 2
Karnofsky
90 - 100%
WHO
< 2
WHO
≤ 2
ECOG
≤ 2
n.r. n.r. Karnofsky
> 50%
Abbreviations: n.r. not reported
PS: Performance status according to inclusion criteriaW
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Table 3: Characteristics and quality of studies
Nordlinger,
2008
Lorenz, 2005 Portier, 2006 Langer, 2002 Kemeny, 2002 Rudroff,
1998
Lygidakis, 1995 Wagman, 1990
Therapy regimen FOLFOX 4, systemic 5-FU/FS, HAI 5-FU/FS, systemic 5-FU/FS, systemic FUDR, HAI + 5-FU/FS, 
systemic
Mitomycin C + 
5FU/FS, HAI
Immuno-therapy + 
5-FU/FS, HAI
FUDR, HAI
Patients analyzed (n=) 364 226 171 107 109 30 ** 40 11 *
Chemotherapy 182 113 86 52 53 14 20 5
Control 182 113 85 55 56 16 20 6
Received assigned 
treatment (n=)
250
(68,7%)
134
(59,3%)
136
(79,5%)
83
(77,6%)
65
(59,6%)
29
(96,6%)
39
(97,5%)
n.r.
Completed
chemotherapy
(n=)
neoadjuvant: 143
adjuvant: 80
34 54 28 20 13 19 n.r
Underwent
surgery
170 100 82 55 45 16 20 6
Randomisation adequate adequate
(tel. periop)
adequate n.r. adequate
(preop)
adequate
(postop)
adequate adequate
(preop)
R0 - resection 303 189 171 107 unclear 30 37 11
Concealed allocation Unclear unclear unclear n.r. unclear unclear adequate unclear
Blinded evaluation Unclear unclear unclear n.r. unclear unclear unclear unclear
Analysis on ITT basis adequate adequate adequate n.r. inadequate adequate adequate adequate
Primary endpoint PFS OS DFS (2 yrs) OS RFS (4 yrs) OS OS TTF
Secondary endpoint Toxicity Intrahepatic 
recurrence
OS DFS OS RFS Intrahepatic 
recurrence
OS; RR
Follow-up (Months) 45 18 87.4 - 51 144 - -
Quality High high high low low low low low
* The total number of trial patients exceeds the sum of patients in groups due to multi-arm design.
** The total number of trial patients exceeds the sum of patients in groups because 12 patients with Dukes A/B were not randomized in this trial.
Abbreviations. pre: randomisation took place pre-operatively, post: randomisation took place
Post-operatively; Peri: randomisation took place during surgery;Wieser et al. BMC Cancer 2010, 10:309
http://www.biomedcentral.com/1471-2407/10/309
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Overall survival
In all eight studies, OS was either a primary or secondary
outcome variable. In the trial by Nordlinger et al. [15] OS
has not yet been reported. The results of all the studies
included indicated no reduction in overall mortality
attributable to the administration of chemotherapy (HR,
0.94; 95% CI, 0.8-1.10; p = 0.43). This result was homoge-
neous (I2 = 26%). Looking at the results in the pre-speci-
fied subgroups, trials involving intra-arterial
chemotherapy failed to show a survival benefit (HR, 1.0;
95% CI, 0.84-1.21; p = 0.96; I2 = 30%).
With respect to the four trials in which R0 resections
were reported [10-13], the results of HAI chemotherapy
did not significantly change (HR, 0.95; 95% CI, 0.78-1.16;
p = 0.6).
The two trials on systemic chemotherapy failed to pro-
vide significant improvement in long-term OS compared
with surgery alone in the initial analysis as single trials.
Our meta-analysis showed a firm tendency towards
better OS for the systemic therapy subgroup (HR, 0.74;
95% CI, 0.53-1.04; p = 0.08; I2 = 0%; Table 4, Figure 3).
Because both treatment modalities were combined in
the Kemeny et al. trial [9], we included this trial in the
systemic therapy subgroup for one separate calculation.
The results showed a decreased chance of improvement
with systemic therapy alone from 26% to only 8% (HR,
0.92; 95% CI, 0.7-1.21; p = 0.54), which might reflect the
possible negative effects of HAI observed in other HAI
trials.
Recurrence-free survival
At first, the fixed effect model was used for meta-analysis.
The results showed a significant improvement for the
peri-operative chemotherapy group as a whole (HR, 0.77;
95% CI, 0.67-0.88; p = 0.0001), with the effect being simi-
lar in both subgroups (HR, 0.78; 95% CI, 0.65-0.95; p =
0.01 for HAI; and HR, 0.75; 95% CI, 0.62-0.91; p = 0.003
for systemic therapy; Table 5, Figure 4).
The heterogeneity was minimal between all of the
included studies (I2 = 25%).
Considering only the three trials of higher quality (HR,
0.82; 95% CI, 0.70-0.96) [11,15,20], the results did not dif-
fer significantly compared to all eight trials (HR, 0.77;
95% CI, 0.67-0.88)
Despite a suboptimal regime which was standard at the
time recruitment started, the two randomized trials
investigating the effect of systemic adjuvant therapy with
5 FU/FA showed a trend towards a better RFS in one
study (39 months vs. 20 months; HR, 0.78; 95% CI, 0.46-
1.32; p = 0.35) [17], and a significant improvement in RFS
in the other trial (24.4 months vs. 17.6 months; HR, 0.66;
95% CI, 0.46-0.96; p = 0.028) [20]. The Nordlinger trial
Table 4: Overall Survival (OS)
Nordlinger Lorenz Portier Langer Kemeny Rudroff Lygidakis Wagman
Median OS time 
(months)
Chemotherapy - 34.5 62.1 53 34.2 - 20 37.3
Control - 40.8 46.4 43 47.5 - 11 28.3
OS at last follow-up 
(cumulative %)
Chemotherapy - - 51.1 57 37 25 95 -
Control - - 41.1 47 49.3 31 80 -
Hazard Ratio - 1.313 0.733 0.773 1.39 1 1.131 0.842 0.712
SE - 0.21 0.21 0.30 0.24 0.41 0.12 0.77
P value - 0.15 0.13 0.39 0.19 0.77 < 0.001 0.66
1 HRs were calculated based on the IPD reconstruction technique
2 only RR could be abstracted
3 HRs were abstracted from original reportsWieser et al. BMC Cancer 2010, 10:309
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[15] tested pre-and post-operative chemotherapy with
FOLFOX 4 versus surgery alone. The study failed to dem-
onstrate a significant improvement in RFS for the peri-
operative chemotherapy group in the intent-to-treat pop-
ulation, which might in part be due to the fact that in the
EORTC trial [15], only 63% of patients received the
intended post-operative treatment.
Subgroup analysis included all three trials and revealed
a significant benefit in RFS (HR, 0.75; 95% CI, 0.62-0.91; p
= 0.003) for the systemic therapy group.
In the trial by Kemeny at al. [9], systemic as well as
locoregional treatment modalities were combined. RFS
and recurrence in the liver were significantly reduced
with manageable toxicities. The 25% risk reduction of
recurrence attained with systemic therapy was similar
when the Kemeny trial [9] was included in this subgroup
(HR, 0.73; 95% CI, 0.6 1-0.88; p = 0.0007).
On the contrary, in the first interim analysis of the Ger-
man trial on adjuvant HAI chemotherapy, Lorenz et al.
[11] reported a median survival of 34.5 months for the
adjuvant HAI therapy group compared with 40.8 months
for the surgery group; the median time to progression
was not improved. Because of possible harmful effects of
HAI observed in this analysis, further accrual of patients
Figure 3 Overall Survival. Overall survival with peri-operative chemotherapy compared with surgery alone. The summary hazard ratio (HR) was 0.94 
(95% CI, 0.80-1.10; P = 0.43) for peri-operative chemotherapy compared with surgery alone.
Table 5: Recurrence - free survival (RFS)
Nordlinger Lorenz Portier Langer Kemeny Rudroff Lygidakis Wagman
Median RFS time (months)
Chemotherapy 18.7 21.6 24.4 39 - - - 30.7
Control 11.7 24.0 17.6 20 - - - 8.7
RFS at last follow-up 
(cumulative %)
Chemotherapy 35.4 33.3 33.5 45 45.7 15 100 -
Control 28.1 36.7 26.7 35 25.2 23 55 -
Hazard Ratio/RR 0.793 0.952 0.663 0.783 0.561 1.121 0.62 0.22
SE 0.13 0.13 0.19 0.27 0.3 0.42 0.18 0.89
P value 0.058 0.72 0.028 0.35 0.04 0.79 < 0.001 0.03
1 HRs were calculated based on the IPD reconstruction technique
2 only RR could be abstracted
3 HRs were abstracted from original reportsWieser et al. BMC Cancer 2010, 10:309
http://www.biomedcentral.com/1471-2407/10/309
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was stopped prematurely. These discrepant results might
be due to the fact that the German study used a different
chemotherapy regimen (FUDR vs. FU/FS) and a different
schedule (5 days vs. 28 days). It remains unclear how
much systemic therapy really adds to the positive results
reported by Kemeny et al. [9].
Subgroup analysis of all five trials using regional ther-
apy showed a significant benefit in RFS conferred by HAI
(HR, 0.78; 95% CI, 0.65-0.95; p = 0.01).
Because heterogeneity between studies in the HAI sub-
group was high (I2 = 54%), we applied the random effects
model to estimate the overall treatment effect of locore-
gional treatment on RFS.
After adjustment for heterogeneity, results were no lon-
ger significant (HR, 0.72; 95% CI, 0.51-1.02; P = 0.07).
When only those trials which reported clear R0 resec-
tions were taken into account, the HR for RFS in the HAI
subgroup did not fundamentally change (HR, 0.81; 95%
CI, 0.67-1.00) compared with all five trials in this sub-
group.
Toxicity
The most frequent grade 3 and 4 toxicities of peri-opera-
tive chemotherapy are listed in Table 6.
The toxicity profiles were obtained for 330 patients
(62.9%) of the 525 patients assigned to the chemotherapy
arms.
Toxicities were generally mild and acceptable. Grade 3-
4 leucopenia and grade 3-4 neutropenia were observed in
4.9% and 13% of patients, respectively. Grade 3 or more
severe nausea and vomiting, diarrhea, and hepatic toxic-
ity were observed in 13.9%, 7.3%, and 6.4% of the patients
who received peri-operative chemotherapy.
Langer and Rudroff [12,17] did not provide any infor-
mation about possible side effects of chemotherapy, while
Wagman [13] reported grade 4 gastrointestinal, hemato-
logic, and neurologic toxicity without further specifica-
tion.
In the Nordlnger trial [15], peri-operative complica-
tions occurred more often in the chemotherapy group
(25% vs. 16%, p = 0.04). Mortality rates were low in both
groups and there was no suspected chemotherapy-associ-
ated deaths in this trial.
The pump placement showed no effect on operative
complications in the Kemeny trial [9], whereas Lorenz et
al. [11] reported a 7.5% early (within 30 days following
surgery) treatment-related mortality rate for the HAI
chemotherapy group.
Altogether, there were 10 treatment-related deaths
(12%) in two trials on intrahepatic chemotherapy [11,13]
Discussion
In the present meta-analysis, we have included, for the
first time, several randomized controlled trials (RCTs)
Figure 4 Recurrence-free survival. Recurrence-free survival with peri-operative adjuvant chemotherapy compared with surgery alone. The summa-
ry hazard ratio (HR) was 0.77 (95% CI; 0.67- 0.88; P = 0.0001) for peri-operative chemotherapy compared with surgery alone.Wieser et al. BMC Cancer 2010, 10:309
http://www.biomedcentral.com/1471-2407/10/309
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involving stage IV CRC in which a patient group with
peri-operative treatment was compared with a group
undergoing surgery alone.
The peri-operative chemotherapy was delivered via dif-
ferent routes of application (systemically, intra-arterially
or both).
Considering all included trials, the HR estimates sug-
gested that peri-operative chemotherapy yielded no sur-
vival advantage over surgery alone (HR, 0.94; 95% CI, 0.8-
1.10; p = 0.43). With respect to RFS, the peri-operative
treatment group had a significant survival benefit (HR,
0.77; 95% CI, 0.67-0.88; p = 0.0001).
We undertook further subset analyses due to the differ-
ent routes of application.
With respect to systemic therapy, the clinical use of
adjuvant chemotherapy in stage III colorectal cancer is
well-established, so one may well think that patients with
resected stage IV CRC might also benefit from adjuvant
treatment. However, in this cancer stage a formal proof of
a better OS was still missing. Existing trials had to close
prematurely because of slow accrual. A control arm for
surgery alone was needed, but difficult to obtain [26].
As a result of our subset analysis, we were able to show
that systemic chemotherapy yielded a significant survival
benefit concerning RFS for the patient group with peri-
operative systemic therapy compared to surgery alone in
patients with resected stage IV CRC.
The results showed a clear tendency towards better OS
after systemic adjuvant therapy with bolus 5FU/FA. The
OS data from the Nordlinger trial [15] are expected in
2010.
As subset analysis has thus demonstrated the useful-
ness of systemic chemotherapy, the question remains
whether or not locoregional chemotherapy would be as
beneficial for operable patients as systemic chemother-
apy.
Since the liver is the most common site of recurrence
after resection of colorectal liver metastases, locoregional
adjuvant treatment might be a reasonable treatment
modality, but its widespread use is limited for several rea-
sons. The application of regional chemotherapy to the
liver requires arterial catheter placement, which is fre-
quently associated with catheter complications, such as
infections, hematomas, or thromboses, meaning in-hos-
pital stays for several days or even weeks and substantial
discomfort for the patient. Moreover, locoregional che-
motherapy does not control occult systemic metastasis.
According to our analysis, the results at first showed a
significant improvement in RFS for the locoregional che-
motherapy group (HR, 0.78; 95% CI, 0.65-0.95; P = 0.01).
After adjustment for heterogeneity, the results were no
longer significant (HR, 0.72; 95% CI, 0.51-1.02; P = 0.07).
OS was not improved.
Our results are thus in agreement with other analyses.
In 2006, Nelson [27] considered seven randomized trials
Table 6: Most frequent grade 3 to 4 toxicities of peri-operative chemotherapy
Nordlinger Lorenz Portier Langer Kemeny Rudroff Lygidakis Wagman
Assessable patients (n =) 115* 73 81 n.r. 30 n.r. 20 11
Gastrointestinal toxicity +
Diarrhea 6 10 7 n.r. 1 n.r. -
Stomatitis - 35 6 n.r. - n.r. 1
Nausea/Vomiting 8 25 6 n.r. 5 n.r. 2
Hepatic 6 7 - n.r. 8 n.r. -
Hematologic toxicity 6 +
Leucopenia 14 - - n.r. 2 n.r. -
Neutropenia 40 - - n.r. - n.r. 3
Thrombopenia 8 - - n.r. 1 n.r. -
Neurologic toxicity +
Sensory neuropathy 11 - 2 n.r. - n.r. -
Fever 19
Treatment-related death 0. 8 0 n.r 0 n.r. 0 2
Abbreviations:
* only the toxicity of post-operative chemotherapy is reported here
+ in this trial only general information about toxicity is provided
n.r. not reportedWieser et al. BMC Cancer 2010, 10:309
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addressing this issue with locoregional treatment. He
found no survival benefit for the group that received HAI.
Even though two trials applied additional systemic che-
motherapy, the results were slightly in favour of the con-
trol group (8.9% survival advantage), although this effect
was not significant (HR, 1.089; 95% CI, 0.887-1.334). In
the pooled analysis by Mitry et al. [14], two studies were
considered. The investigators found a marginal statistical
benefit in favor of adjuvant therapy concerning median
progression free survival (p = 0.058). In evaluating OS,
however, they could only demonstrate a non-significant
improvement (p = 0.095).
Yet several problems remain unresolved.
Peri-operative chemotherapy can be further divided
into two clearly defined treatment modalities (the pre-
operative [neoadjuvant] treatment and the post-operative
[adjuvant] treatment). Since the EORTC trial [15] was
intended to demonstrate that chemotherapy combined
with surgery is a better treatment than surgery alone, and
not to compare pre- vs. post-operative chemotherapy, the
exact role of pre-operative chemotherapy in the case of
initially resectable liver metastases remains unknown and
cannot be answered with data from the aforementioned
trials.
Additionally we analyzed patients with partially
unknown post-operative resection status (R0 vs. R1) who
received different types of chemotherapy regimens as one
group.
The heterogeneity among trials in the HAI subgroup
may be a limitation of our meta-analysis, even though we
applied a random-effect model that takes possible hetero-
geneity into consideration.
Although the study by Nordlinger et al. [15] included
more patients than the previously reported pooled analy-
sis by Mitry et al. [14] and employed a more effective reg-
imen, we found no evidence of study heterogeneity in
relation to the graphical or statistical methods within the
systemic therapy group.
Regarding the role of FOLFIRI as another effective che-
motherapy regimen in the adjuvant treatment of CRC,
the study by Ychou et al. [18] showed no significant
improvement in disease-free survival (DFS) compared
with 5FU/FA.
Grade 3/4 toxic effects were more common in patients
treated with FOLFIRI vs. 5 FU/FA (47% vs. 30%), with
neutropenia being the most common (23% vs. 7%).
Thus, further clarification of which patient group
would benefit by peri-operative chemotherapy, whether
applied pre- or post-operatively, and which drug or com-
bination of drugs would be most effectively applied, is
essential.
The results of further studies will hopefully elucidate
the most suitable treatment modality in operable
patients.
Although compliance to systemic treatment appeared
to be acceptable in the trials that were included in our
analysis (66.7% and 63% of the planned treatments)
[15,20], further efforts to improve chemotherapeutic reg-
imens to minimize toxicities are clearly warranted.
Some technical aspects should be mentioned in relation
to this meta-analysis.
All our analyses were based on abstracted data and not
on individual patient data (IPD). The results must there-
fore be interpreted cautiously, as an IPD-based meta-
analysis would give a more reliable estimation than one
based on abstracted data.
Additionally, for reasons of general applicability, we
chose RFS as the common endpoint of our analysis.
Assuming a R0 resection in all patients, we considered
it appropriate to translate the respective endpoints of the
analyzed trials, such as progression-free survival (PFS) or
disease-free survival (DFS) into recurrence - free survival
(RFS).
In the original report, DFS was calculated from the
time of resection until recurrence or death of any cause
[20]. Langer [17] did not provide an exact definition of
DFS.
Kemeny [9] chose the 4-year recurrence-free rate as a
primary endpoint in her trial and calculated from the
date of randomisation. In the trial by Rudroff et al. [12]
the recurrence-rate was a secondary outcome variable
estimated from the date of liver resection. The secondary
outcome variable recurrence in the liver was calculated
from the date of randomisation in the Lorenz trial [11].
Lygidakis [10] reported on intrahepatic recurrence with-
out further time to event assessment. PFS was counted
from the date of randomisation until progressive disease
or recurrence or death of any cause in the Nordlinger trial
[15].
Follow-up intervals were similar in all except one trial.
The respective endpoint in the six-armed Wagman trial
[13] was TTF and was calculated from the day of surgery.
Here, TTF was chosen because the other groups (arms
B1, B2, C1, und C2) were not rendered disease-free at the
time of randomisation. In this trial no further informa-
tion about follow-up intervals was provided.
Yet in spite of some differences in the respective end-
points, between-study variability was quite low among all
the eight trials which were included (I2 = 25%).
The inclusion of results presented in the abstract form,
which may be only preliminary, might also have biased
our final results. However, since our analysis of Langer
and Portier [17,20] correlated well with the pooled analy-
sis by Mitry et al. [14], which was based on IPD, any bias
due to this factor is likely to be small.
The accuracy of the HRs estimated from the survival
curves is another important issue. We obtained fairly
good correlation between the HRs reported in the articlesWieser et al. BMC Cancer 2010, 10:309
http://www.biomedcentral.com/1471-2407/10/309
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and those obtained based on the published survival
curves, suggesting that curve-based HRs can be substi-
tuted in cases where the HRs are not available.
Conclusions
In conclusion, this is the first meta-analysis to demon-
strate the benefit of systemic peri-operative chemother-
apy in the treatment of patients with resected stage IV
CRC. Even though the strength of our main conclusion
was limited by the fact that it was based on abstracted
data, peri-operative chemotherapy should be recom-
mended in case of initially resectable metastases of CRC.
Our results should be confirmed by an IPD-based
meta-analysis.
Competing interests
D. Arnold: Honoraria: Roche, Sanofi, Pfizer, Amgen, Merck. Research funding:
Roche, Sanofi, Pfizer.
W. Schmiegel: Honoraria: Merck, Roche, Abbott, Amgen, Pfizer, Falk. Research
Funding: Roche, Sanofi-Aventis. Travel Support: Roche, Merck, Astra-Zeneca.
Advisory role: Roche, Amgen, Astra-Zeneca.
A. Reinacher-Schick: Honoraria: Amgen, Roche, Sanofi, Pfizer. Research funding:
Roche, Sanofi.
Authors' contributions
MW participated in the design and coordination of the study, performed the
statistical analysis and drafted the manuscript. ARS conceived of the study, par-
ticipated in its design and helped to draft the manuscript. SS performed the
statistical analysis. DA participated in the design of the study and helped to
draft the manuscript WS conceived of the study and participated in its design.
All authors read and approved the final manuscript.
Acknowledgements
The work was supported by the P.U.R.E Research Program funded by the State 
Ministry for Innovation, Science, Research and Technology of Northrhine-West-
falia and the FoRUM foundation of the Ruhr-University Bochum.
We wish to thank David Cushley for providing a language edited revision of our 
paper.
Author Details
1Department of Internal Medicine, Knappschaftskrankenhaus Bochum 
Langendreer, University of Bochum, Bochum, Germany, 2Institute for Clinical-
Oncological Studies within P.U.R.E., University Bochum, Bochum, Germany, 
3Institute for Research in Operative Medicine, University of Witten/Herdecke, 
Cologne, Germany and 4Department of Hematology and Oncology, University 
of Halle, Germany
References
1. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004.  Ann 
Oncol 2005, 16(3):481-488.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009.  
CA: a cancer journal for clinicians 2009, 59(4):225-249.
3. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002.  CA: a 
cancer journal for clinicians 2005, 55(2):74-108.
4. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, 
Turnbull AD, Sullivan D, Stockman J, et al.: Hepatic arterial infusion of 
chemotherapy after resection of hepatic metastases from colorectal 
cancer.  The New England journal of medicine 1999, 341(27):2039-2048.
5. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, 
Kemeny N, Brennan MF, Blumgart LH, D'Angelica M: Actual 10-year 
survival after resection of colorectal liver metastases defines cure.  J 
Clin Oncol 2007, 25(29):4575-4580.
6. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero 
AM, Prasad M, Blumgart LH, Brennan MF: Liver resection for colorectal 
metastases.  J Clin Oncol 1997, 15(3):938-946.
7. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger 
F, Levi F, Bismuth F: Five-year survival following hepatic resection after 
neoadjuvant therapy for nonresectable colorectal.  Annals of surgical 
oncology 2001, 8(4):347-353.
8. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, 
Jaeck D: Surgical resection of colorectal carcinoma metastases to the 
liver. A prognostic scoring system to improve case selection, based on 
1568 patients. Association Francaise de Chirurgie.  Cancer 1996, 
77(7):1254-1262.
9. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson 
ER, O'Dwyer PJ, Benson AB: Combined-modality treatment for 
resectable metastatic colorectal carcinoma to the liver: surgical 
resection of hepatic metastases in combination with continuous 
infusion of chemotherapy--an intergroup study.  J Clin Oncol 2002, 
20(6):1499-1505.
10. Lygidakis NJ, Ziras N, Parissis J: Resection versus resection combined 
with adjuvant pre- and post-operative chemotherapy--
immunotherapy for metastatic colorectal liver cancer. A new look at an 
old problem.  Hepato-gastroenterology 1995, 42(2):155-161.
11. Lorenz M, Muller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K, Hauss J, 
Stieger R, Jauch KW, Bechstein WO, et al.: Randomized trial of surgery 
versus surgery followed by adjuvant hepatic arterial infusion with 5-
fluorouracil and folinic acid for liver metastases of colorectal cancer. 
German Cooperative on Liver Metastases (Arbeitsgruppe 
Lebermetastasen).  Annals of surgery 1998, 228(6):756-762.
12. Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J: Prospective 
randomised trial on adjuvant hepatic-artery infusion chemotherapy 
after R0 resection of colorectal liver metastases.  Langenbeck's archives 
of surgery/Deutsche Gesellschaft fur Chirurgie 1999, 384(3):243-249.
13. Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty JD, Kokal WA, 
Riihimaki DU: A prospective, randomized evaluation of the treatment of 
colorectal cancer metastatic to the liver.  J Clin Oncol 1990, 
8(11):1885-1893.
14. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, 
Elias D, O'Callaghan C, et al.: Adjuvant chemotherapy after potentially 
curative resection of metastases from colorectal cancer: a pooled 
analysis of two randomized trials.  J Clin Oncol 2008, 26(30):4906-4911.
15. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, 
Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al.: 
Perioperative chemotherapy with FOLFOX4 and surgery versus 
surgery alone for resectable liver metastases from colorectal cancer 
(EORTC Intergroup trial 40983): a randomised controlled trial.  Lancet 
2008, 371(9617):1007-1016.
16. Sampson M, Barrowman NJ, Moher D, Klassen TP, Pham B, Platt R, St John 
PD, Viola R, Raina P: Should meta-analysts search Embase in addition to 
Medline?  Journal of clinical epidemiology 2003, 56(10):943-955.
17. Langer Bernhard HB, Labianca Roberto, Shepherd Lois, Nitti Donato, 
Marsoni Silvia, Tu Dongsheng, Sargeant Ann-Marie, Fields Anthony, 
University of Toronto, Toronto, ON, Canada; Institute Jules Bordet, Brussels, 
Belgium; Ospedali Riuniti, Bergamo, Italy; NCIC CTG, Queens University, 
Kingston, ON, Canada; University of Padova, Padova, Italy; South Europe 
New Drugs Organization, Milan, Italy; Cross Cancer Inst, Edmonton, AB, 
Canada: Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation 
after potentially curative resection of liver or lung metastases from 
colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) 
randomized trial.  Proc Am Soc Clin Oncol 2002, 21:. (abstr 592)
18. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, 
Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A: A 
randomized phase III study comparing adjuvant 5-fluorouracil/folinic 
acid with FOLFIRI in patients following complete resection of liver 
metastases from colorectal cancer.  Ann Oncol 2009, 20(12):1964-1970.
19. Tono T, Hasuike Y, Ohzato H, Takatsuka Y, Kikkawa N: Limited but definite 
efficacy of prophylactic hepatic arterial infusion chemotherapy after 
curative resection of colorectal liver metastases: A randomized study.  
Cancer 2000, 88(7):1549-1556.
20. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, 
Piedbois P, Guimbaud R, Nordlinger B, et al.: Multicenter randomized trial 
of adjuvant fluorouracil and folinic acid compared with surgery alone 
Received: 31 January 2010 Accepted: 21 June 2010 
Published: 21 June 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/309 © 2010 Wieser et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:309Wieser et al. BMC Cancer 2010, 10:309
http://www.biomedcentral.com/1471-2407/10/309
Page 13 of 13
after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 
trial.  J Clin Oncol 2006, 24(31):4976-4982.
21. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform 
meta-analyses of the published literature for survival endpoints.  
Statistics in medicine 1998, 17(24):2815-2834.
22. Messori A TS, Vaiani M, et al.: Survival meta-analysis of individual patient 
data and survial meta-analysis of published (aggregate) data: Is ther an 
intermediate approach between these two opposite options?  Clin 
Drug Invest 2000, 20:309-316.
23. Lopez-Ladron AJS, Bernabe R, Bernardos A, Arriola E, Serrano J, Reina JJ, 
Gomez MA, Barneto I, Moreno-Nogueira JA, Hospital Virgen Rocio, Sevilla, 
Spain; Hospital JR Jimenez, Huelva, Spain; Hospital Reina Sofia, Cordoba, 
Spain: Observation versus postoperative chemotherapy after resection 
of liver metastases in patients with advanced colorectal cancer.  Proc 
Am Soc Clin Oncol 2003, 22:. (abstr 1497)
24. Asahara T, Kikkawa M, Okajima M, Ojima Y, Toyota K, Nakahara H, 
Katayama K, Itamoto T, Marubayashi S, One E, et al.: Studies of 
postoperative transarterial infusion chemotherapy for liver metastasis 
of colorectal carcinoma after hepatectomy.  Hepato-gastroenterology 
1998, 45(21):805-811.
25. Kemeny MM, Goldberg D, Beatty JD, Blayney D, Browning S, Doroshow J, 
Ganteaume L, Hill RL, Kokal WA, Riihimaki DU, et al.: Results of a 
prospective randomized trial of continuous regional chemotherapy 
and hepatic resection as treatment of hepatic metastases from 
colorectal primaries.  Cancer 1986, 57(3):492-498.
26. Kokudo N, Hasegawa K, Makuuchi M: Control arm for surgery alone is 
needed but difficult to obtain in randomized trials for adjuvant 
chemotherapy after liver resection for colorectal metastases.  J Clin 
Oncol 2007, 25(10):1299-1300. author reply 1300
27. Nelson R, Freels S: Hepatic artery adjuvant chemotherapy for patients 
having resection or ablation of colorectal cancer metastatic to the 
liver.  Cochrane database of systematic reviews (Online) 2006:CD003770.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/309/prepub
doi: 10.1186/1471-2407-10-309
Cite this article as: Wieser et al., Peri-operative chemotherapy for the treat-
ment of resectable liver metastases from colorectal cancer: A systematic 
review and meta-analysis of randomized trials BMC Cancer 2010, 10:309